Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan

Executive Summary

A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.

You may also be interested in...



BsUFA Revenue Missed Estimates Again In FY2019

US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.

Biosimilar User Fee Revenue Missed Estimates Again In FY 2019, Spending Reduced

US FDA said that total BsUFA obligations also decreased compared to estimates, but maintains optimism about future revenue increases.

Playing It Safe? Hahn's Biosimilar View

US FDA Commissioner nominee gave a general, scripted answer to a question about biologic patents, but did Stephen Hahn inadvertently go against the agency's stance on the issue?

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS140985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel